Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Immunotherapy in Patient With Poor General Condition
- Status
- COMPLETED
- Phase
- PHASE2
Microbiome Immunotherapy Toxicity and Response Evaluation
- Status
- UNKNOWN
- Phase
- N/A
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Long-Term Safety and Efficacy Study
- Status
- COMPLETED
- Phase
- PHASE4
TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2